WASHINGTON, D.C. (September 29, 2025) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced three major actions as part of the biopharmaceutical industry’s commitment to American patients and workers.
PhRMA member companies are making historic investments in U.S.-based manufacturing and infrastructure, providing financial assistance to millions of insured and underinsured patients who have been failed by a broken health insurance system, and announcing a new website that will simplify access to manufacturer direct purchase and patient assistance resources.
“For more than 40 years, the U.S. has led the world in biopharmaceutical innovation—delivering lifesaving treatments and supporting millions of American jobs,” said Stephen J. Ubl, president and CEO of PhRMA. “Today, we’re building on that legacy and answering President Trump’s call to put America first by strengthening America’s leadership, improving access for patients and supporting good-paying jobs. But we can’t do it alone. We need policymakers to protect innovation, fix the broken insurance system that burdens patients with high out-of-pocket costs, and ensure foreign governments pay their fair share.”
To put America first, the biopharmaceutical industry is:
- Delivering $500 billion in new U.S.-based infrastructure investments. These bold investments will generate an estimated $1.2 trillion in economic output and create 100,000+ new jobs including 25,000 biopharmaceutical jobs. PhRMA member companies’ direct investments create a ripple effect leading to indirect benefits to local economies, creating more demand for goods and services, childcare, education, recreational activities and more.President Trump’s leadership to enact comprehensive tax reform and streamline federal regulations helped enable these investments, which depend on the U.S. maintaining a supportive and predictable policy and regulatory environment without new government price controls and tariffs. Imposing new tariffs on medicines would undermine new U.S. investments because every dollar spent on a tariff is a dollar not available to build in America or discover cures.
- Providing 10 million Americans each year with financial assistance to help fill the gaps for patients failed by a broken health insurance system. Too many Americans face barriers to accessing their medicines with patients facing rising out-of-pocket costs and insurers excluding more medicines from formularies. According to a new survey, PhRMA member companies help 10 million patients annually through patient assistance and co-pay support programs where patients can get their medicine for free, nearly free or receive financial support to cover burdensome cost-sharing requirements. For two decades, PhRMA has been helping connect patients, caregivers and health care providers to manufacturer support including through the Medicine Assistance Tool (MAT.org), featuring more than 750 resources.
- Announcing AmericasMedicines.com, a new website that will connect patients with manufacturer direct purchase programs. There is growing recognition that PBMs and other middlemen receive massive rebates on medicines while charging patients the full price and putting up barriers to access. This is why President Trump called on companies to let patients and employers purchase medicines directly – and at a lower cost. Some manufacturers are responding by offering new direct purchase programs that are more convenient and can save patients time and money – no hidden markups or fees and transparent pricing for patients and businesses.
PhRMA will be launching AmericasMedicines.com in January 2026, a new website to help patients more easily access these programs. This new website will allow manufacturers to list a wide range of medicines and connect patients directly to available options prescribed by their doctor. Pharmaceutical manufacturers must make their own decisions to offer direct purchase programs, determine how they will work and if they want to participate in AmericasMedicines.com.
PhRMA will continue to work with the administration and Congress to address the real reasons U.S. medicine prices are higher. Other countries continue to undervalue medical innovation, while middlemen here at home collect half of every dollar spent on brand medicines. These imbalances drive up costs for everyone. To reduce price differentials with other wealthy countries, policymakers should require PBMs to share savings with patients, fix the 340B hospital markup program and force foreign governments to pay their fair share.
To learn more, visit AmericasMedicines.com.